Oral Oncology Reports (Sep 2024)

Nivolumab (Opdivo) in PD-1 pathway inhibition: Enhancing immune response in recurrent oral squamous cell carcinoma

  • J. Nandhini,
  • E. Karthikeyan

Journal volume & issue
Vol. 11
p. 100630

Abstract

Read online

No abstracts available.